ReviewBMC methods2026
A novel bone and cancer cells co-culture methodology to model breast cancer metastasis to bone ex vivo.
Review in BMC methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: One of the major challenges in late-stage cancer research is studying the direct interactions between cancer cells and the metastatic tissue. Metastasis is an inefficient multistep process in which only a small subset of cancer cells successfully colonizes the new microenvironment. Bone is the most common tissue for breast and prostate cancer metastasis and the third most common site across all cancer types. We present an ex vivo co-culture protocol for modeling bone metastasis that enables direct investigation of cancer cell interactions with the native bone and marrow microenvironment. Methods: The procedure involves the extraction and preparation of mouse long bones (femurs and tibiae), injection of cancer cells into the bone marrow cavity, maintenance of the co-culture, and sample processing for downstream analysis. The protocol supports functional readouts, including bioluminescence imaging of tumor cell viability, conditioned media sampling, and downstream tissue analysis, such as immunohistochemistry or micro-computed tomography (µCT). The culture setup procedure can be completed in a single day, and daily media maintenance thereafter requires minimal time. Final sample processing times vary, depending on the analysis completed. Discussion: The system maintains viable and metabolically active bone, marrow, and cancer cells for up to four weeks and preserves the heterogeneity of the bone microenvironment. It is highly adaptable for various cancer types and bone genotypes and enables high-throughput functional interrogation of cancer colonization in a complex microenvironment. The protocol requires basic expertise in mammalian cell culture and mouse dissection and is suitable for researchers studying metastasis, tumor-stroma interactions, or preclinical therapeutic screening in the bone microenvironment. Clinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.